Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Scarlett Bone

Nurse Practitioner, Family Fort Smith, AR Nurse Practitioner

NPI 1790274355 CMS profile 10423523

5921 Riley Park Dr, Fort Smith, AR 72916

Open in the dashboard

General payments

$16,306

607 records reported · program years 2021–2025

Research payments

$5,340

Paid to them · 30 records reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Scarlett Bone of Fort Smith, AR is reported in the CMS Open Payments database as having received $16,306 across 607 general payments and $5,340 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,822 119
2024 General $2,836 121
2024 Research $3,228 19
2023 General $2,852 119
2023 Research $2,112 11
2022 General $2,889 118
2021 General $3,906 130

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Scarlett Bone
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Scarlett Bone were reported at $3,822. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Scarlett Bone Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $3,906 $124 $35–$379 $132
2022 $2,889 $141 $44–$430 $149
2023 $2,852 $154 $49–$476 $160
2024 $2,836 $165 $51–$504 $164
2025 $3,822 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Eli Lilly and Company $2,475 2 payments
  2. Novartis Pharmaceuticals Corporation $1,929 37 payments
  3. Arcutis Biotherapeutics, Inc. $1,179 14 payments
  4. AbbVie, Inc. $1,073 65 payments
  5. Janssen Biotech, Inc. $1,046 55 payments
  6. Amgen Inc. $943 43 payments
  7. Dermavant Sciences, Inc. $863 38 payments
  8. UCB, Inc. $838 51 payments
  9. Regeneron Healthcare Solutions, Inc. $813 35 payments
  10. Lilly USA, LLC $764 40 payments
  11. Other $4,382 227 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $12,039 597 payments
  2. Consulting Fee $3,075 3 payments
  3. Travel and Lodging $861 2 payments
  4. Education $330 5 payments
Products named General payments · program years 2021–2025
  1. Zoryve $1,004 8 payments
  2. VTAMA $959 40 payments
  3. Otezla $943 43 payments
  4. TREMFYA $935 48 payments
  5. DUPIXENT Immunology $773 29 payments
  6. TALTZ $764 40 payments
  7. SKYRIZI $581 39 payments
  8. OPZELURA $494 29 payments
  9. CIBINQO $454 32 payments
  10. DUPIXENT Inflammation And Immunology $428 21 payments
  11. Other $6,401 365 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. Sanofi US Services Inc. $4,086 22 payments
  2. AbbVie, Inc. $1,254 8 payments

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

714

Median for Nurse Practitioner: 389

Drug cost

$241,952

Median for Nurse Practitioner: $21,885

Branded share of claims

13.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 48 $209,674
Zoryve Roflumilast Brand 23 $20,842
Ketoconazole Generic 104 $2,407
Mometasone Furoate Generic 90 $2,093
Tacrolimus Generic 19 $1,801
Doxycycline Hyclate Generic 90 $1,619
Triamcinolone Acetonide Generic 136 $1,257
Clobetasol Propionate Generic 21 $811
Spironolactone Generic 50 $363
Methotrexate Methotrexate Sodium Brand 28 $361

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$53,287

Medicare's payments for the services billed

Medicare patients

404

Average age 75

Services billed

1,756

252 women, 152 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Ischemic heart disease 30%
Diabetes 27%
Chronic kidney disease 26%
Depression 23%
Osteoporosis 21%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zoryve
  • Arcutis Biotherapeutics, Inc. $744
$744 23 —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $167
  • GENZYME CORPORATION $82
$250 48 —
TREMFYA
  • Janssen Biotech, Inc. $231
$231 — —
Otezla
  • Amgen Inc. $215
$215 — —
VTAMA
  • Dermavant Sciences, Inc. $201
$201 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

637 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record